Dirk Arnold
迪尔克·阿诺德
MD, PhD
Director, Asklepios Tumor Center Hamburg汉堡阿斯克勒庇俄斯肿瘤中心主任
👥Biography 个人简介
Prof. Dirk Arnold is a principal author of ESMO metastatic CRC clinical practice guidelines and led the FIRE-3 trial comparing cetuximab versus bevacizumab in first-line treatment. His work defines evidence-based standards for systemic therapy of metastatic CRC in Europe.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FIRE-3 Trial Leadership
Led the FIRE-3 phase III trial comparing cetuximab versus bevacizumab combined with FOLFIRI in first-line KRAS wild-type metastatic CRC, demonstrating overall survival benefit with cetuximab and refining treatment sequencing strategies.
ESMO CRC Guidelines Authorship
Served as lead or co-author on multiple editions of ESMO metastatic CRC clinical practice guidelines, synthesizing global trial data into practical treatment algorithms adopted across European oncology centers.
Representative Works 代表性著作
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic CRC (FIRE-3)
The Lancet Oncology (2014)
Phase III FIRE-3 trial demonstrating OS benefit for cetuximab versus bevacizumab in first-line KRAS wild-type mCRC.
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology (2023)
Updated ESMO guidelines providing evidence-based treatment recommendations for metastatic colorectal cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 迪尔克·阿诺德 的研究动态
Follow Dirk Arnold's research updates
留下邮箱，当我们发布与 Dirk Arnold（Asklepios Tumor Center Hamburg / Asklepios Klinik Altona）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment